देश: यूनान
भाषा: अंग्रेज़ी
स्रोत: HMA (Heads of Medicines Agencies)
amoxicillin trihydrate 500 mg, clavulanic acid 125 mg
Le Vet B.V
QJ01CR01
Tablet
ampicillin and enzyme inhibitor
Cats, Dogs
2011-03-30
Page 1 of 17 SUMMARY OF PRODUCT CHARACTERISTICS 2 1. NAME OF THE VETERINARY MEDICINAL PRODUCT CLAVUBACTIN® 500/125 MG tablets for dogs 2. QUALITATIVE AND QUANTITATIVE COMPOSITION ACTIVE SUBSTANCES: _quantity _ Amoxicillin (as amoxicillin trihydrate) 500 mg Clavulanic acid (as potassium clavulanate) 125 mg EXCIPIENT(S): Saccharin sodium 7.00 mg For a full list of excipients, see section 6.1. 3. PHARMACEUTICAL FORM Tablet Yellowish-white to light yellow oblong-formed tablet with round edges and embossement 625 on one side. 4. CLINICAL PARTICULARS 4.1 TARGET SPECIES Dogs 4.2 INDICATIONS FOR USE, SPECIFYING THE TARGET SPECIES Treatment of infections in dogs caused by bacteria sensitive to amoxicillin in combination with clavulanic acid, particularly: - Skin infections (including superficial and deep pyodermas) associated with Staphylococci (including beta-lactamase producing strains) and Streptococci. - Urinary tract infections associated with Staphylococci (including beta-lactamase producing strains), Streptococci, _Escherichia coli _(including beta-lactamase producing strains), _Fusobacterium _ _necrophorum _and _Proteus spp_. - Respiratory tract infections associated with Staphylococci (including beta-lactamase producing strains), Streptococci and Pasteurellae. - Enteritis associated with _Escherichia coli _(including beta-lactamase producing strains) and Proteus spp. - Infections of the oral cavity (mucous membrane) associated with Clostridia, Corynebacteria, Staphylococci (including beta-lactamase producing strains), Streptococci, _Bacteroides spp _ (including beta-lactamase producing strains), _Fusobacterium necrophorum _and Pasteurellae. पूरा दस्तावेज़ पढ़ें